Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Prostate Cancer
37%
Fluorodeoxyglucose F 18
34%
Prostate Specific Membrane Antigen
34%
Positron Emission Tomography
33%
Fluorodeoxyglucose
28%
Gallium 68
26%
Positron Emission Tomography
26%
Positron Emission Tomography - Magnetic Resonance Imaging
24%
Diagnosis
23%
Neoplasm
21%
Magnetic Resonance Imaging
21%
Nuclear Magnetic Resonance
20%
Breast Cancer
17%
Biological Marker
16%
Radiomics
15%
Standardized Uptake Value
14%
Computer Assisted Tomography
13%
Fluorine-18
12%
Axillary Lymph Node
11%
Disease
11%
Esophageal Cancer
11%
Overall Survival
10%
Lymph Node
10%
Radiation Therapy
9%
Pelvis
9%
Metastatic Carcinoma
9%
Neoadjuvant Therapy
8%
Retrospective Study
8%
Symptom
8%
Diffusion MRI
7%
Progression Free Survival
7%
Non Small Cell Lung Cancer
7%
Radioisotope
7%
Cervical Cancer
7%
Diagnostic Performance
7%
Stereotactic Body Radiation Therapy
7%
Axillary Lymphadenopathy
7%
Lutetium 177
7%
Liver Metastasis
7%
Hyperbaric Medicine
7%
Neuroendocrine Tumor
7%
Fibroblast
7%
Protein Inhibitor
7%
Amyloid
7%
Cancer Staging
6%
Image Quality
5%
COVID-19 Vaccination
5%
Prospective Study
5%
COVID-19
5%
Keyphrases
Positron Emission Tomography-computed Tomography (PET-CT)
81%
Prostate-specific Antigen
39%
PET-MRI
34%
Positron Emission Tomography
27%
SUVmax
21%
Magnetic Resonance
17%
Standardized Uptake Value
17%
FDG Uptake
17%
Hyperbaric Oxygen
16%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
14%
Prostate Cancer
13%
Magnetic Resonance Imaging
12%
18F-FDG PET-CT
11%
Axillary Lymph Node
11%
Seizure
11%
CT Radiomics
11%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
11%
Radionuclide Therapy
11%
Breast Cancer
10%
Lutetium-177 (177Lu)
10%
Whole-body
10%
Vaccination
9%
Same-day
9%
18F-fluorodeoxyglucose PET
8%
Overall Survival
8%
COVID-19
8%
Israel
8%
Metabolic Tumor Volume
8%
Computed Tomography
8%
Hyperbaric Oxygen Therapy
8%
Prostate-specific Membrane Antigen Positron Emission Tomography
8%
Progression-free Survival
8%
18F-fluorodeoxyglucose (18F-FDG)
8%
Apparent Diffusion Coefficient
7%
Abdominal
7%
Diffusion-weighted Imaging
7%
Diagnostic Performance
7%
PSMA PET-CT
7%
Gallium-68
7%
Fibroblast Activation Protein Inhibitor
7%
Esophageal Cancer
7%
Pathological Response
7%
Diffusion Magnetic Resonance Imaging (dMRI)
7%
Cervical Cancer
7%
Simultaneous Image
7%
Image Features
7%
Liver Metastasis
7%
Image Model
7%
Repeatability
7%
Model Estimation
7%